10% Owner Lynx1 Buys $885K of Korro Bio Stock in Four Open-Market Trades
KRRO has more than doubled off its 52-week low of $5.204.
Summary
Korro Bio 10% owner Lynx1 Capital bought 79,809 shares for $884,752 in open-market trades from October 22 to 26, lifting its indirect stake to 1,624,789 shares.
Key Events · Ownership and Investor Activity · KRRO
-
10% Owner Adds 79,809 Shares
Lynx1 Capital Management LP and Weston Nichols reported four open-market purchases totaling 79,809 shares for $884,751.91 between 2026-10-22 and 2026-10-26.
-
Weighted-Average Prices $9.68 to $12.11
Trades were struck at weighted-average prices of $9.6764, $11.0366, $12.1061 and $11.7454, with each reported price a blend of multiple fills inside a stated range.
-
Stake Rises to 1,624,789 Shares
Post-transaction indirect holdings via Lynx1 Master Fund LP reached 1,624,789 shares, up from 1,557,155 after the first purchase.
-
Buying Follows KRRO-111 Data
The purchases began on 2026-10-22, the same day Korro released preclinical KRRO-111 data showing >95% SERPINA1 editing, and continued through 2026-10-26.
Analysis · KRRO · Life Sciences
Lynx1 Capital Management, whose GP is solely managed by Weston Nichols, deployed $884,752 of real money into KRRO across four sessions, buying from $9.68 up to $12.11. That equals roughly 0.5% of the company's market value, and it lands days after the 2026-10-22 preclinical KRRO-111 data release—so a large holder is adding after the news rather than trimming. The caveat: this is a financial 10% owner, not an operator, so the read-through is weaker than a CEO purchase would be. It also runs against the 90-day pattern of net insider selling ($1.18M), making the reversal in direction the notable part.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRRO was trading at $12.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177M. The 52-week trading range was $5.20 to $42.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.